Paradigm Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Paradigm Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-900	Closed	-$84.3K	–	537
2017 Q2	$84.3K	Sell	900 -900	-50%	-$55.1K	0.02%	447
2017 Q1	$115K	Buy	+1,800	New	+$109K	0.02%	490
2015 Q4	–	Sell	-32,100	Closed	-$2.95M	–	869
2015 Q3	$2.95M	Sell	32,100 -10,700	-25%	-$926K	0.39%	84
2015 Q2	$3.76M	Hold	42,800	–	–	0.42%	81
2015 Q1	$3.18M	Buy	42,800 +40,500	+1,761%	+$2.86M	0.35%	90
2014 Q4	$129K	Hold	2,300	–	–	0.02%	517
2014 Q3	$104K	Sell	2,300 -2,500	-52%	-$104K	0.01%	545
2014 Q2	$199K	Sell	4,800 -550	-10%	-$28.3K	0.03%	490
2014 Q1	$371K	Hold	5,350	–	–	0.05%	380
2013 Q4	$322K	Hold	5,350	–	–	0.05%	433
2013 Q3	$325K	Buy	+5,350	New	+$379K	0.05%	395

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paradigm Asset Management's CLVS Position: Q3 2017 in Review

Paradigm Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 900 shares — an estimated $84.3K sold.

Paradigm Asset Management first reported a position in CLVS in Q3 2013 and held it in 11 quarters. The position peaked at $3.76M in Q2 2015. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Paradigm Asset Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 900 Clovis Oncology, Inc. shares in Q3 2017, an estimated $84.3K.
Paradigm Asset Management first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 11 quarters.
Paradigm Asset Management's Clovis Oncology, Inc. position peaked at $3.76M in Q2 2015.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.